As consideration for the amended and restated distribution and licensing agreement, Angiotech will receive $25 million. Angiotech and Baxter initially entered into a distribution and licensing agreement in
Bill Gates joined Chinese Minister of Health Chen Zhu to announce an innovative partnership to help fight a serious tuberculosis epidemic in China. The goal of the partnership
The grants by the Connecticut Stem Cell Advisory Committee were made under a 2005 state law which designated $100 million over 10 years to promote stem cell research
Key Figures and Financial Highlights : Full year revenue EUR2.6 million and other income of EUR1.1 million Operational costs reduced by close to EUR1 million to EUR16.5 million
Neurotech Pharmaceuticals, a biotechnology company, has announced that the company’s lead product candidate, NT-501, substantially slowed the loss of vision in a Phase II clinical trial in subjects
Agfa HealthCare said that the new cardiology system will include solutions for adult and pediatric echocardiography, cardiac catheterization, and vascular ultrasound. IMPAX Cardiovascular provides diagnosticians with a single
Western Maryland Regional Medical Center (WMHS) will rely on Agfa HealthCare’s IMPAX Cardiovascular (IMPAX CV) for all cardiology studies, including cardiac catheterization imaging and echocardiography imaging and reporting.
At December 31, 2008, the company had liquid funds available for operating activities, comprised of cash and cash equivalents together with current investments, of $3.7 million, compared to
Endocyte, a biotechnology company, has announced positive interim results from an ongoing Phase II clinical study of EC145 in patients with advanced non-small cell lung cancer. The single
Trubion Pharmaceuticals, a biopharmaceutical company, has announced that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth, has initiated a Phase I clinical trial of SBI-087, Trubion’s next
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.